Pfizer CEO is Upbeat About Non-COVID-Related Performance CEO Bourla was bullish on the company's non-COVID performance in Q1 2024
Yoshinaga S, Hauptmann M, Sigurdson AJ, et al
I think the very important thing for this trial is, it is a different kind of patient population
The retrospective nature also prevents investigators from accounting for non-adherence, which may explain the worsening of glycemic control for a small subset of patients in the case series
Research published in the Journal of Clinical Endocrinology and Metabolism describes the clinical consequences of delayed gastric emptying with both GLP-1 receptor agonists and tirzepatide, noting that the dual GIP/GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists
Safe, non-invasive, and advanced treatment with visible reduction in melanin synthesis